Preeclampsia Screening and Prevention by Dr L. Musara.

Item: Preeclampsia Screening and Prevention by Dr L. Musara.
Rating: 4
Author: PostSingularity Institute

by Dr L. Musara

Life & Natural Systems Medicine & Health MKCGynaecology and obstetrics MKCMMaterno-foetal medicine

🎙 Dr L. Musara 👥 2K 📅 May 28, 2026 ⏱ 17 min 👁 40 📄 expert opinion 🧭 2026-08-16

Available in: English (current) Français

Keywords

preeclampsiascreeningFMFaspirinbiomarkers

Summary

Dr L. Musara presents on preeclampsia screening and prevention, emphasizing the importance of early detection and prophylaxis. He discusses the prevalence and impact of preeclampsia, highlighting that it affects 2-5% of pregnancies globally and up to 8-12% in Africa, contributing to significant maternal and neonatal mortality. The presentation reviews various prediction models, with the FMF (Fetal Medicine Foundation) model showing superior predictive value. He details the components of the FMF model: maternal risk factors, mean arterial pressure (MAP), uterine artery pulsatility index (PI), and biochemical markers (PAPP-A, PlGF). He explains proper measurement techniques for MAP and uterine artery Doppler, and the role of biochemical markers like PlGF and sFlt-1. He emphasizes that aspirin prophylaxis can reduce early-onset preeclampsia by 62% if started before 16 weeks. He discusses the FIGO and WHO guidelines, advocating for universal screening at 11-13+6 weeks. He addresses challenges in low-resource settings, including cost and availability of tests, and argues that screening should be offered to all patients, as it is cost-effective compared to managing complications. He concludes that accurate prediction and prophylaxis can reduce adverse outcomes, and that using only history is ineffective.

187 words

Critical Evaluation

Value of the Information & Strength of the Argument

The presentation provides valuable information on preeclampsia screening, particularly the FMF algorithm, which is evidence-based and recommended by international guidelines. The speaker effectively argues for the superiority of the FMF model over history-based screening, citing detection rates and meta-analyses. He also addresses practical aspects, such as proper MAP measurement and uterine artery Doppler technique, which are crucial for accurate screening. The argumentation is coherent, with a clear progression from the problem of preeclampsia to the solution of screening and prevention. However, the presentation is largely an expert opinion without detailed statistical evidence or references to specific studies, which limits its scientific rigor.

Scientific Rigor, Source Quality, Title Accuracy

The presentation references established guidelines (NICE, FIGO) and the FMF algorithm, which are well-regarded in obstetrics. It also mentions studies by Dr. S. Ngwenya, but without specific citations. The title accurately reflects the content. The speaker does not provide direct URLs or detailed references, but the information aligns with current medical knowledge. The presentation is suitable for a professional audience, though it lacks formal citations.

182 words

Title / Content Match

The title accurately reflects the content, which focuses on screening and prevention of preeclampsia.

Quality & Reliability

7/10

The presentation is based on established guidelines (NICE, FIGO) and the FMF algorithm, with references to published studies. However, it is an expert opinion without detailed citations or peer-reviewed sources in the video itself.

Key Moments

Markers derived by PSI from the transcript: the creator did not define chapters.

Cited Sources

Fetal Medicine Foundation (FMF) preeclampsia screening algorithm — Mentioned as the basis for the screening model.
NICE guideline on hypertension in pregnancy — Referenced for risk factors and aspirin prophylaxis.
FIGO guidelines on preeclampsia screening — Mentioned as supporting universal screening.

Concurring Sources

Fetal Medicine Foundation (FMF) preeclampsia screening algorithm — The FMF model is widely validated and recommended.
NICE guideline on hypertension in pregnancy — Supports aspirin for high-risk women.

Contribution & Novelties

The presentation offers a practical guide for implementing preeclampsia screening in low-resource settings, emphasizing the use of maternal factors, MAP, and uterine artery Doppler, which can achieve a 96% detection rate for early-onset preeclampsia without biochemical markers. It also highlights the importance of offering all available tests to patients, regardless of cost assumptions.

Pour aller plus loin :

Fetal Medicine Foundation — Official site for the FMF algorithm and training.
NICE guideline NG133 — UK guideline on hypertension in pregnancy.
FIGO guidelines — International guidelines on preeclampsia screening.
Placental growth factor (PlGF) testing — Review on PlGF in preeclampsia prediction.
Aspirin for prevention of preeclampsia — Evidence on aspirin prophylaxis.

110 words

Radar Profile

The radar profile shows high scores in information quantity and technical level, indicating a detailed and specialized presentation. The quality and reliability scores are moderate, reflecting the lack of formal citations. The overall balance suggests a valuable educational resource for clinicians.

Reliability 7/10